JPRN-jRCT2080221009未知1 期
A Phase I Study of ARQ 197 in Combination with Erlotinib in Patients with Advanced/Recurrent Non-Small-Cell Lung Cancer
Kyowa Hakko Kirin Co., Ltd.0 个研究点开始时间: 2010年2月17日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Voluntary written informed consent for study participation must be obtained
- •- A histologically or cytologically confirmed advanced/recurrent non-small-cell lung cancer
- •- History of >=1 prior chemotherapy regimen (treatment with EGFR tyrosine kinase inhibitors will be counted as one regimen)
- •- ECOG PS of 0 or 1
- •- Life expectancy of >=3 months
排除标准
- •- Anti-cancer chemotherapy, anti-cancer therapy with EGFR-TKI, hormone therapy, radiotherapy, immunotherapy, other investigational agents or anti-cancer antibody therapy within 28 days prior to ARQ 197 dose
- •- Surgery for cancer within 28 days prior to ARQ 197 dose
- •- Positive for HBs antigen, HCV antibody or HIV antibody
- •- Active double cancer
- •- Known symptomatic brain metastases
- •- An intercurrent illness that is uncontrolled (e.g., infection, symptomatic congestive heart failure, unstable angina pectoris, symptomatic arrhythmia, interstitial pneumonia)
- •- Pregnant or lactating
- •- Subjects who wish to have a child and who would not agree to use contraceptive measures
研究者
相似试验
未知
1 期
A Phase I Study of ARQ 197 in Combination with ErlotinibAdvanced/recurrent non-small-cell lung cancerJPRN-jRCT2080221318Kyowa Hakko Kirin Co., Ltd.
已完成
1 期
A Study of ARQ 197 in Combination With ErlotinibNon-small-cell Lung CancerNCT01069757Kyowa Kirin Co., Ltd.16
已完成
1 期
A Study of ARQ 197 in Combination With ErlotinibAdvanced/Recurrent Non-small-cell Lung CancerNCT01251796Kyowa Kirin Co., Ltd.9
进行中（未招募）
不适用
A Randomized Phase 2 Study of ARQ 197 versus Investigator’s Choice of Second-Line Chemotherapy in Patients with Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment with One Prior Chemotherapy RegimeEUCTR2007-004622-25-LVArQule Inc.338
进行中（未招募）
不适用
A Randomized Phase 2 Study of ARQ 197 versus Gemcitabine in Treatment-naïve Patients with Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinomanresectable Locally Advanced or Metastatic Pancreatic AdenocarcinomaMedDRA version: 9.1Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticEUCTR2007-002727-32-LVArQule Inc.72